Chen Schor, Adicet CEO

Adicet un­veils ear­ly re­spons­es for off-the-shelf drug lever­ag­ing rare T cells. Will dura­bil­i­ty hold up?

On the hunt for the next gen­er­a­tion of “off-the-shelf” cell ther­a­pies, biotech play­ers like Adicet Bio have looked to lever­age some of the less-ob­vi­ous mem­bers …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.